These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25640025)

  • 1. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
    Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival.
    Yang JZ; Lian WG; Sun LX; Qi DW; Ding Y; Zhang XH
    Pathol Res Pract; 2016 Mar; 212(3):210-6. PubMed ID: 26774288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma.
    Ortega MM; Melo MB; De Souza CA; Lorand-Metze I; Costa FF; Lima CS
    Ann Hematol; 2003 Jul; 82(7):405-9. PubMed ID: 12783209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
    Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
    Tucker SM; Zaihra T
    Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
    Wang J; Shen N; Shen X; Zhang R; Jin Y; Li J; Chen L
    Ann Med; 2023; 55(2):2281657. PubMed ID: 38086395
    [No Abstract]   [Full Text] [Related]  

  • 11. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis.
    Yang JZ; Wu XD; Meng JB; Zhang JQ; Sun LX
    Pathol Res Pract; 2018 Oct; 214(10):1694-1699. PubMed ID: 30196985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
    Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
    Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetics of extramedullary manifestations in multiple myeloma.
    Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
    Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
    Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of TP53 mutation in myeloma.
    Chng WJ; Price-Troska T; Gonzalez-Paz N; Van Wier S; Jacobus S; Blood E; Henderson K; Oken M; Van Ness B; Greipp P; Rajkumar SV; Fonseca R
    Leukemia; 2007 Mar; 21(3):582-4. PubMed ID: 17215851
    [No Abstract]   [Full Text] [Related]  

  • 18. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
    Chang H; Qi C; Yi QL; Reece D; Stewart AK
    Blood; 2005 Jan; 105(1):358-60. PubMed ID: 15339849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
    Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.